TARRYTOWN, N.Y. - The U.S. Food and Drug Administration (FDA) has expanded the approval for Dupixent® (dupilumab) to include adolescent patients aged 12 to 17 with inadequately controlled chronic ...

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...

Vejdirektoratet oplyser til B.T., at uheldet har forårsaget, at der lige nu ligger olie på vejen, hvilket forsinker trafikken, men redningen er på stedet. Forlænget rejsetid er lige nu mellem 10 og 30 ...

This is the ninth indication for DUPIXENT ® in Canada and its second in gastroenterology 1 Expanded indication marks second disease for which DUPIXENT ® is approved in children this young in the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

This is the ninth indication for DUPIXENT ® in Canada and its second in gastroenterology 1 Expanded indication marks second disease for which DUPIXENT ® is approved in children this young in the ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Sanofi’s (Euronext: SAN) mega blockbuster drug Dupixent (dupilumab) as an add-on maintenance ...

The LIBERTY-CUPID C study enrolled CSU patients aged six years and older who remained symptomatic despite standard-of-care (SOC) antihistamines and were not previously treated with Novartis NVS ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous ...